Farms.com Home   Ag Industry News

DowDuPont merger approved by European Union

Merger could be completed by late 2017

By Diego Flammini
Assistant Editor, North American Content
Farms.com

The European Commission (EC), the European Union’s (EU) top regulatory agency, conditionally approved the merger between Dow and DuPont.

The approval is contingent upon Dow and DuPont to divest itself of certain portfolios.

“DuPont will divest itself of its cereal broadleaf herbicides and chewing insecticides portfolios,” the companies said in a release. "DuPont will also divest its crop protection research and development pipeline and organization, excluding seed treatment, nematicides, and late-stage R&D programs, which DuPont will continue to develop and bring to market…”

Dow will divest itself of its acid copolymers and ionomers businesses.

The EC outlined three concerns surrounding the merger:

1.     Reducing competition in a number of markets for existing pesticides,

2.     Reducing innovation competition for pesticides, and

3.     Reducing competition for certain petrochemical products.

Dow and DuPont offered a set of commitments to address the European Commissions’ concerns.

The agricultural companies said they would preserve price and innovation competition in pesticide markets and preserve competition for certain petrochemical products.

 In its ruling, the EC said it continues to examine the proposed acquisition of Syngenta by ChemChina.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.